TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Iol Chem And Pharma Ltd
IOLCP

Iol Chem And Pharma Ltd Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 56/100 · Average See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹204.19

Change

+0.97 (0.48%)

Open

₹203.25

Prev. Close

₹203.22

Day High

₹206.5

Day Low

₹198.01

Volume Analysis

Traded

2,455,948

Delivered

509,690

Delivery %

20.75%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Promoter holding is rising

Weaknesses (1)

  • •Low return on equity (8.41%)

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹216.28 ₹211.39 ₹207.79 ₹202.9 ₹199.3 ₹194.41 ₹190.81
Fibonacci ₹211.39 ₹208.15 ₹206.14 ₹202.9 ₹199.66 ₹197.65 ₹194.41
Camarilla ₹206.52 ₹205.75 ₹204.97 ₹202.9 ₹203.41 ₹202.63 ₹201.86

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+148.47%

1 Week

+0.63%

1 Month

+4.74%

3 Months

+40.54%

6 Months

+163.71%

1 Year

+96.58%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹80.43

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

8.63%

Net margin 6.66% × asset turnover 0.9x × equity multiplier 1.44x

Company Overview

Sector

Healthcare

Market Cap

₹5,965 Cr

P/E (TTM)

33.8

ROE

8.41%

Book Value

₹61.3

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.

TopFund Analysis

Iol Chem And Pharma Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 56/100. The strongest factor is Financial Strength (100/100), while Growth (4/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (8.41%). FII holding has been rising.

TopFund Score — Fundamentals Quality

56/100 — Average

Data confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

4

Valuation

41

Cash Flow

48

Corporate Governance

100

Momentum

89

Institutional Ownership

44

Business Quality

52

Risk & Volatility

43

Liquidity

51

From Screener.in

  • +Company is almost debt free.
  • +Company has been maintaining a healthy dividend payout of 22.1%
  • +Promoter holding has increased by 4.80% over last quarter.
  • −Stock is trading at 3.32 times its book value
  • −Company has a low return on equity of 7.72% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

EU-REACH Registration For Triacetin 23 Sep

On 23 Sep 2026, IOLCP received EU-REACH registration for Triacetin, enabling exports across EU.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 Sep 23 Sep
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 Sep

IOLCP will host a virtual investor meeting with Nuvama PCG on 28 Sept 2026.

Dispatch Of Reminder Letter To Shareholders To Update KYC 21 Sep

IOLCP dispatched reminder letters on 19 Sep 2026 to physical shareholders to update KYC details.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 17 Sep

IOLCP discussed ₹500 crore capex for Ibuprofen, CDMO and specialty chemicals; commercialization starts FY27-FY29.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 563 545 520 504 502 526 523 528 552 568 580 619 756
Expenses + 491 481 476 454 451 484 476 465 490 510 523 527 653
Operating Profit 73 64 44 50 51 42 47 63 62 57 57 92 103
OPM % 13.0% 12.0% 9.0% 10.0% 10.0% 8.0% 9.0% 12.0% 11.0% 10.0% 10.0% 15.0% 14.0%
Other Income + 7 7 8 8 7 6 4 5 7 7 -6 2 8
Interest 4 4 4 3 2 4 4 4 4 3 4 3 4
Depreciation 14 16 16 16 17 18 19 19 20 20 20 20 21
Profit before tax 61 51 32 37 40 26 28 45 46 40 28 71 87
Tax % 25.0% 26.0% 28.0% 26.0% 24.0% 26.0% 26.0% 30.0% 25.0% 26.0% 25.0% 25.0% 26.0%
Net Profit + 46 38 23 28 30 19 21 31 34 30 21 53 64
EPS in Rs 2 1 1 1 1 1 1 1 1 1 1 2 2
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 2,184 2,217 2,133 2,079 2,319 2,524
Expenses + 1,925 1,991 1,902 1,877 2,049 2,213
Operating Profit 259 226 231 202 270 310
OPM % 12.0% 10.0% 11.0% 10.0% 12.0% 12.0%
Other Income + 17 25 30 22 9 11
Interest 8 16 16 15 15 14
Depreciation 43 46 63 72 80 82
Profit before tax 225 189 182 138 184 226
Tax % 25.0% 26.0% 26.0% 27.0% 25.0% —
Net Profit + 168 139 134 101 138 168
EPS in Rs 6 5 5 3 5 6
Dividend Payout % 14.0% 17.0% 22.0% 23.0% 21.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 1,334 1,449 1,553 1,629 1,740
Borrowings + 44 80 33 117 135
Other Liabilities + 526 435 600 577 653
Total Liabilities 1,962 2,022 2,244 2,382 2,587
Fixed Assets + 561 752 933 1,171 1,182
CWIP 105 90 101 22 96
Investments 2 20 20 21 21
Other Assets + 1,294 1,161 1,190 1,169 1,289
Total Assets 1,962 2,022 2,244 2,382 2,587
Equity Capital 59 59 59 59 59

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 93 122 290 179 214
Cash from Investing Activity + -121 -120 -191 -154 -198
Cash from Financing Activity + -2 -4 -92 46 -29
Net Cash Flow -29 -2 6 70 -13
CFO/OP 60 75 144 97 93
Free Cash Flow -58 -87 17 -34 43

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 48.19% → 62.28%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 49.12% 49.27% 50.11% 50.34% 50.11% 45.81% 45.84% 44.76% 45.1% 45.26% 40.78% 32.41%
Promoters 48.19% 48.19% 48.19% 48.19% 48.19% 52.62% 52.62% 52.62% 52.62% 52.62% 57.48% 62.28%
FII 2.33% 2.18% 1.4% 1.39% 1.63% 1.49% 1.47% 2.59% 2.25% 2.08% 1.72% 4.87%
DII 0.35% 0.36% 0.29% 0.09% 0.07% 0.08% 0.07% 0.02% 0.05% 0.03% 0.02% 0.43%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Iol Chem And Pharma Ltd (this stock) 5,965 33.8 3.31 8.41%
Artemis Med Service Ltd 5,917 51.0 6.34 12.0%
Senores Pharmaceuticals L 6,241 49.4 6.67 13.4%
Fdc Limited 5,641 18.3 2.26 11.2%
Orchid Pharma Limited 6,377 353.0 3.55 1.49%
Symbiotec Pharmalab Ltd 6,447 64.8 — 11.7%
Gujarat Themis Biosyn Ltd 5,442 112.0 — —

Which Mutual Funds Hold Iol Chem And Pharma Ltd?

Frequently Asked Questions about Iol Chem And Pharma Ltd

Community Sentiment

What are other investors saying about Iol Chem And Pharma Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.